Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: Liquidia Corporation, 3 years.
Liquidia Corporation
Director
Candel Therapeutics Inc.
Director
Verrica Pharmaceuticals Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 16, 2024 | Candel Therapeutics Inc. | Open-market purchase | +500,000 | $6.00 | $3,000,000 |
| Dec 16, 2024 | Candel Therapeutics Inc. | Open-market purchase | +750,000 | $6.00 | $4,500,000 |
| Nov 26, 2024 | Verrica Pharmaceuticals Inc. | Gift | −450,000 | — | — |
| Nov 22, 2024 | Verrica Pharmaceuticals Inc. | Open-market purchase | +18,426,966 | — | — |
| Nov 22, 2024 | Verrica Pharmaceuticals Inc. | Open-market purchase | +4,494,382 | — | — |
| Sep 19, 2024 | Verrica Pharmaceuticals Inc. | Gift | −2,675,611 | — | — |
| Sep 19, 2024 | Verrica Pharmaceuticals Inc. | Gift | +891,870 | — | — |
| Sep 19, 2024 | Verrica Pharmaceuticals Inc. | Gift | +891,870 | — | — |
| Sep 19, 2024 | Verrica Pharmaceuticals Inc. | Gift | +891,870 | — | — |
| Sep 12, 2024 | Liquidia Corporation | Open-market purchase | +337,078 | $8.90 | $2,999,994 |
| Jun 27, 2024 | Taysha Gene Therapies Inc. | Open-market purchase | +1,333,333 | $2.25 | $2,999,999 |
| Jun 20, 2024 | Liquidia Corporation | Grant or award | +20,359 | — | — |
| Dec 14, 2023 | Liquidia Corporation | Open-market purchase | +279,330 | $7.16 | $2,000,003 |
| Nov 17, 2023 | Taysha Gene Therapies Inc. | Open-market purchase | +100,000 | $1.63 | $163,000 |
| Aug 16, 2023 | Taysha Gene Therapies Inc. | Open-market purchase | +16,466,667 | $0.90 | $14,820,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.